Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Poniard Pharmaceuticals |
---|---|
Information provided by: | Poniard Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00478946 |
Colorectal cancer is a type of cancer that begins in the large intestine (colon) or the rectum (end of the colon). Several drugs are often given in combination to treat colorectal cancer. One of the most active treatment combinations is known as FOLFOX, which is a combination of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin. Oxaliplatin is a type of platinum drug and was approved by the FDA in 2004. While generally well-tolerated, oxaliplatin may cause toxicity to the nerves, such as sensory loss or cold sensitivity.
Picoplatin is a new type of platinum drug that has shown activity with 5-FU in pre-clinical studies and has undergone extensive Phase 1 and Phase 2 testing in a variety of cancers. No significant nerve toxicity has been seen in previous studies of picoplatin.
This study will review the safety and effectiveness of FOLPI, which is the combination of 5-FU and leucovorin with picoplatin in participants with colorectal cancer.
Condition | Intervention | Phase |
---|---|---|
Colorectal Cancer |
Drug: (FOLPI) Picoplatin with 5-FU and Leucovorin Drug: FOLPI Drug: FOLFOX |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety Study |
Official Title: | A Phase I Open-Label Study of Picoplatin in Combination With 5-Fluorouracil and Leucovorin as Initial Therapy in Subjects With Metastatic Colorectal Cancer |
Estimated Enrollment: | 43 |
Study Start Date: | April 2006 |
Estimated Study Completion Date: | June 2010 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
|
Drug: (FOLPI) Picoplatin with 5-FU and Leucovorin
Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
Drug: FOLPI
Picoplatin, 150 mg/m2 to be administered with every alternate cycle of 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W, will be administered as a 2-hour infusion, either alone or, if the patient is to receive picoplatin that cycle, at the same time as picoplatin, in separate bags using a Y-line. The leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
|
2: Active Comparator
FOLFOX Oxaliplatin 85 mg/m2, as a 2-hour infusion Leucovorin (400 mg/m2 in D5W) and Oxaliplatin. Leucovorin + oxaliplatin will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
|
Drug: FOLFOX
Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
|
Subjects will be randomized centrally to treatment with picoplatin administered either every two or every four weeks and will be assigned a dose of picoplatin dependent on the study results to date. Each patient will also receive therapy every two weeks with 5-FU and leucovorin. In each schedule, the cohort size will be 3 subjects, to be expanded to 6 subjects if a dose-limiting toxicity is observed. If not dose-limiting toxicity observed among the 3 subjects within a cohort, picoplatin dose escalation may proceed, until the maximum tolerated dose is established.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Russian Federation | |
St. Petersburg Mechnikov State Medical Academy - Phase 2 | |
St. Petersburg, Russian Federation, 195067 | |
Blokhin Russian Oncology Research Center - Phase 1 | |
Moscow, Russian Federation, 115478 | |
St. Petersburg City Oncology Center - Phase 1 | |
St. Petersburg, Russian Federation, 198255 | |
Semashko Central Clinical Hospital #2 - Phase 1 | |
Moscow, Russian Federation, 129128 | |
St. Petersburg Academy of Postgraduate Education - Phase 2 | |
St. Petersburg, Russian Federation, 194291 | |
Yaroslavl Regional Oncology Center - Phase 1 | |
Yaroslavl, Russian Federation, 150054 | |
Medical Radiology Research Center of Russian Academy of Medical Sciences- Phase 1 | |
Obninsk, Russian Federation, 249036 | |
Chelyabinsk Regional Oncology Center - Phase 1 | |
Chelyabinsk, Russian Federation, 454087 | |
Regional Oncology Center - Phase 2 | |
Astrakhan, Russian Federation, 414041 | |
Voronezh Regional Clinical Oncology Center - Phase 2 | |
Voronezh, Russian Federation, 394000 | |
Republic Oncology Center of the Ministry of Healthcare of Karelia Republic - Phase 2 | |
Petrozavodsk, Russian Federation, 185007 | |
Regional Clinical Oncology Center - Phase 2 | |
Ulyanovsk, Russian Federation, 432063 | |
Rostov Research Institute of Oncology- Phase 2 | |
Rostov-na-Dony, Russian Federation, 350086 | |
Regional Oncology Center, Chemotherapy Department - Phase 2 | |
Engels, Russian Federation, 413115 | |
Kazan Oncology Center | |
Kazan, Russian Federation, 420111 | |
Russian Federation, Vsevolozhsk | |
Leningrad Regional Oncology Center, Chemotherapy Department - Phase 2 | |
Kuzmolovsky Village, Vsevolozhsk, Russian Federation, 188663 |
Study Director: | Robert Earhart, MD, PhD | Poniard Pharmaceuticals |
Responsible Party: | Poniard Pharmaceuticals ( Robert Earhart, MD, PhD ) |
Study ID Numbers: | 0501 |
Study First Received: | May 23, 2007 |
Last Updated: | January 20, 2009 |
ClinicalTrials.gov Identifier: | NCT00478946 History of Changes |
Health Authority: | Russia: Pharmacological Committee, Ministry of Health; United States: Food and Drug Administration |
colorectal cancer picoplatin FOLFOX FOLPI chemotherapy |
Vitamin B Complex Digestive System Neoplasms Gastrointestinal Diseases Colonic Diseases Leucovorin Trace Elements Intestinal Diseases Rectal Diseases |
Intestinal Neoplasms Oxaliplatin Digestive System Diseases Fluorouracil Vitamins Gastrointestinal Neoplasms Micronutrients Colorectal Neoplasms |
Digestive System Neoplasms Vitamin B Complex Gastrointestinal Diseases Growth Substances Physiological Effects of Drugs Colonic Diseases Leucovorin Intestinal Diseases Rectal Diseases |
Pharmacologic Actions Intestinal Neoplasms Neoplasms Neoplasms by Site Digestive System Diseases Vitamins Gastrointestinal Neoplasms Micronutrients Colorectal Neoplasms |